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Background 
Vitamin D deficiency has been classically associated with impaired calcium metabolism but 
currently it is known that it also associates with a host of conditions, including obesity, 
cardiovascular disease (CVD) and dementia, and consequently with higher risk of death due to 
these conditions (Barnard 2010). A map of vitamin D receptors highlighted that vitamin D has a 
significant effects on the activity of some 200 human genes, with the vast majority of these 
having no obvious role in calcium management (Ramagopalan 2010). Vitamin D status is 
assessed by measuring circulating levels of 25-hydroxyvitamin D, hereafter referred to as 25D. 
Deficiency of 25D may impact cardiovascular risk in direct and indirect ways by activating the 
renin-angiotensin system and consequently increasing blood pressure, or by influencing the 
parathyroid hormone levels, myocardial function, inflammation and vascular calcification (Lee 
2008). This is not surprising as most tissues, including the cardiac muscle, are able to metabolize 
25D (Norman 2010). Moreover, low 25D status is associated with overweight and obesity 
(Pereira-Santos 2015, Lehtinen-Jacks 2016) which also predisposes to cardiovascular disease. A 
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recent review concluded that all relevant Hill criteria for a causal link in a biological system are 
satisfied to indicate low 25D status as a risk factor for cardiovascular disease (Weyland 2014).  
Based on a 2011 review of cardiovascular events in relation to 25D concentrations including 
studies with follow-up generally up to 15 years, we concluded that cardiovascular risk is 
particularly elevated at ranges below 25-35 nmol/l while potential benefits beyond 60 nmol/l 
remain unclear (Leu 2011). A meta-analysis of prospective studies, including approximately 65 
000 participants, found a relative risk of 1.52 (1.30-1.77) for total CVD and 1.64 (1.27-2.10) for 
stroke for the lowest versus highest 25D category (Wang 2012). Another meta-analysis of 
500 000 participants confirmed a significant inverse relationship for all-cause mortality at 
concentrations less than 75 nmol/l and found no improvement or risk beyond 90 nmol/l 
(Garland 2014). In contrast, other studies found U- or J-shaped associations (Michaelsson 2010, 
Durup 2015). As the correlation between baseline 25D level and risk of disease may diminish 
with length of follow-up (Grant 2011, Grant 2012), widely varying follow-up times could be 
partly responsible for the lack of agreement between the studies. 
In this article we will investigate the risk of incident total CVD, stroke and of all-cause mortality 
in middle-aged women that were followed for more than three decades. As this study provides 
one of the longest follow-ups to date on this topic, we will also examine the impact of follow-up 
length on the observed associations. 
 
Subjects and Methods 
The present study is based on the Population Study of Women in Gothenburg, Sweden. In 1968, 
women born in 1908, 1914, 1918, 1922 and 1930 were systematically sampled from the census 
register to yield a representative sample of 38-, 46-, 50-, 54- and 60-year-old women. Of those 
sampled, 1 462 women (participation rate 90%) participated in an extensive health examination 
in 1968-1969 (described in Bengtsson 1973). The cohort was followed prospectively with four 
re-examinations in 1974-1975, 1981-1982, 1992-1993 and 2000-2001. The Ethics Committee of 
the University of Gothenburg approved the study. All subjects gave written informed consent to 
participate, in accordance with the provisions of the Helsinki Declaration.  
During the baseline visit, fasting blood (120 ml) was drawn from each subject. A small quantity 
was used for immediate analysis and the remainder was stored at -20C. The 25D 
concentrations in the stored samples were analyzed in 2013, as described elsewhere (Lehtinen-
Jacks 2016), for 1 227 women (84% of baseline participants). The validity of 25D in this material 
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has been previously investigated (Leu 2015) and these concentrations were shown to be 
strongly related to weight status in middle- to late-life (Lehtinen-Jacks 2016).   
Baseline height was measured to the nearest 0.5 cm and weight was measured to the nearest 
0.1 kg (Bengtsson 1973). Waist circumference (WC) was measured at the midway level between 
the lower rib margin and the iliac crest. Body mass index (BMI, kg/m2) was calculated. In this 
study, BMI and WC were included as indicators of overall and central adiposity, respectively.  
During the baseline clinical examination, blood pressure (BP) was measured in sitting position. 
Hypertension was defined as systolic BP ≥140 mmHg, diastolic BP ≥ 90 mmHg or as a known 
history of hypertension (with or without antihypertensive medication). Information about 
smoking habits and physical activity during leisure time was obtained via standardized 
interviews (Bengtsson 1973). 
Baseline education and occupational class information (OC; based on the woman’s or her 
husband’s profession, whichever was higher between them, Carlsson 1958) was obtained 
through questionnaires. Finally, season of 25D measurement was defined as early summer 
(May-June), late summer (August-October) or winter (November-April). The categories of the 
background factors as used in the present study are shown in Table 1.  
End points and follow-up time 
Morbidity data and hospital care information (diagnoses and occasions) were obtained through 
interviews by study physicians until 1980 and linkage with the National Patient Register from 
1980 onwards. When judged necessary for adequate diagnosis the researchers examined the 
hospital records and death certificates and data collected at routine examinations. CVD events 
(myocardial infarction, heart failure, stroke and other CVD) were identified by use of ICD-8/9 
codes 390-459 and ICD-10 codes I00-I99. The date of the CVD event was the day the woman 
was admitted to the hospital with the diagnosis. The date of death was established through 
linkage with the national mortality register. 
In the analyses of total CVD and stroke the follow-up started at the baseline examination and 
ended at the time of the respective event, death or on December 31st 2001, whichever occurred 
first. We excluded one participant with a CVD diagnosis before baseline. To examine if the effect 
of baseline 25D varied with the length of follow-up, we performed intermediary analyses where 
the follow-up was interrupted three times, each time decreasing it by five years. Consequently, 
the follow-up was stopped on December 31st 1996, December 31st 1991 and December 31st 
1986, corresponding to 27, 22 and 17 years’ follow-up, respectively. The results are presented in 
chronological order.  
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For all-cause mortality, the end of follow-up was defined as date of death or December 31st 
2006. Intermediary mortality analyses were performed where the follow-up was interrupted 
four times, each time decreasing the length of follow-up with five years. 
 
Statistical methods 
For statistical analyses, 25D values were dichotomized into the lowest quartile (<=51.45 nmol/L; 
“low 25D status”) versus the upper three quartiles combined (“high 25D status”). Differences in 
continuous baseline factors by 25D status were tested with the t-test when the assumption of 
normality was fulfilled or with the Mann-Whitney test otherwise.  Associations between 
categorical factors and 25D status were tested with the χ2-test.  
For each outcome, the survival across 25D categories was visually inspected with unadjusted 
and age- and season-adjusted Kaplan Meier curves. The hazard ratio (HR) in the low 25D 
category was estimated from Cox proportional hazard models (high category as reference). The 
basic Cox models accounted for age at baseline and season of 25D measurement. The fully 
adjusted models accounted for known predictors of CVD morbidity or death, or factors that 
were significantly associated with 25D status.  
Before including categorical covariates into the Cox models, we checked that they were 
significant according to the log-rank test and fulfilled the proportional hazard (PH) assumption 
(visual inspection of the log(-log(survival)) vs log(follow-up time) plot). If this assumption did not 
seem fulfilled, it was further tested through the cumulative sum of martingale residuals (Lin 
1993). This test was used also for continuous predictors. Those covariates that did not fulfill the 
PH assumption and were not of direct interest (age, smoking status and occupational class) 
were used as stratification variables.  
To test the impact of follow-up length on the association between baseline 25D and outcomes, 
interactions between 25D status and time were introduced into the basic models. The test of 
such interaction assumes equality of HRs between adjacent periods and, consequently, 
statistical significance indicates that HR can change with time (see Appendix for details).   
The fully adjusted models were built progressively, based on the entire follow-up time, by 
including potential confounders one at a time. For total CVD incidence and all-cause mortality, 
the final models included (aside from 25D status) age, season of examination, occupational 
class, smoking status, leisure physical activity, waist circumference, hypertension, and 
triglyceride level. For stroke, the selected covariates were similar except for hypertension and 
triglycerides. Total CVD and stroke were also adjusted for education. Collinearity between the 
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variables selected in the final models was examined through the variance inflation factors and it 
was not detected. 
Finally, we investigated if the dilution of HR towards the null (i.e. 1) across increasing periods of 
follow-up could be attributed to the age attained during these periods. As the Cox model did 
not provide enough flexibility to make this distinction, we performed sensitivity analyses using 
the Poisson model. A stratified analysis was run after dichotomizing the follow-up time into 1-17 
vs. more than 17 years, and the age attained during these periods into 38-68 vs. 69-93 years. 
The models were adjusted for season of 25D measurement. 
 All statistical tests were 2-sided with P<0.05 considered statistically significant. All analyses 
were conducted with SAS 9.2 (SAS Institute Inc., Cary, NC, USA).  
Results 
At baseline, 25D status was associated with season of examination, with the lowest prevalence 
of low 25D from August through October (Table 1). Current smokers, women with lower 
occupational class, lower education, obesity and less physical activity had the highest 
prevalence of low 25D. Waist circumference and triglyceride levels were higher for women with 
a low 25D. Age, systolic and diastolic BP, and hypertension and total cholesterol were not 
associated with 25D status. 
Total CVD and stroke incidence  
Women with a low 25D status (<51 nmol/L vs ≥51 nmol/L) had a significantly lower probability 
of remaining free of cardiovascular disease throughout the follow-up time (p-value <0.01; Figure 
1). During the first 17 years, these women had a significantly increased risk of incident CVD, 
HR=1.68 95%CI (1.18; 2.40) (Table 2) according to the basic Cox model. Increasing the follow-up 
with five years decreased the observed association to HR =1.42 (1.07; 1.88) (p for equality of HR 
=0.01). Additional accrual of follow-up time resulted in non-significant HRs. The increased risk at 
17 years was no longer significant in the fully adjusted model.  
Women in the low 25D category were more likely to experience stroke (p<0.01; Figure 2). Their 
relative risk was more than 3-fold at 17 years of follow-up in the basic model and remained 
unchanged in the fully adjusted model (HR=3.30, Table 2). In the basic model, every additional 
five years of follow-up diminished significantly the magnitude of risk, with HR decreasing to 1.74 
at 22 years (p for equality of HRs < 0.01), 1.32 at 27 years (p=0.02) and 1.12 at 32 years (p=0.30). 




In the sensitivity analyses, a significantly increased rate ratio of CVD was observed during the 
initial 17 year period in both age-groups (38-68 and 69-93 years). In contrast, after 17 years, no 
significant risk was found in either age-group. Regarding stroke, a highly increased risk was 
observed during the initial period in the 38-68-year-olds, while among older women the 
association could not be studied because of a limited number of events (n=4). During the 
second period, no significant risk was found in either age-group. 
All-cause mortality  
Subjects with a high 25D status survived significantly longer compared to those with a low 
status (p<0.001; Figure 3). During the initial 17 years there were 115 deaths, representing 15% 
of the subjects with a low 25D status and 7% among those with a high 25D status. Women with 
a low 25D had more than double the risk HR=2.26 (1.49; 3.43) in the basic model (Table 2), 
which decreased to 1.66 (1.38; 1.98) when the whole follow-up was included. For all examined 
periods, this increased risk was not explained by the additional adjustment for covariates but 
was of a lesser magnitude compared to the basic model. In these fully adjusted models, HR was 
2.02 during the first 17 years and 1.43 at 37 years of follow-up.   
 
Discussion 
In this study, middle-aged women who were in the lowest 25D quartile had more than 3-fold 
increase in the risk of stroke and a 2-fold increase in the risk of death when followed for 17 
years. These risks remained basically unchanged after controlling for potential confounders, but 
were weakened by a longer follow-up. The follow-up length had a similar attenuation effect on 
the risk of total CVD. Sensitivity analyses indicated that the diminishing effect of low 25D over 
time is mainly caused by a lengthy follow-up and not by age. 
Such attenuations have also been identified by others in relation to several outcomes (Hernan 
2010, Grant 2012), and their magnitudes differ depending on the disease (Grant 2011, Lim 
2009). In a meta-analysis of 32 000 elderly participants, HR for all-cause mortality per 20 nmol/L 
increase in 25D was attenuated from 0.82 at 6 years of follow-up to 0.96 after 14 years (Grant 
2012). Since our cohort started in mid-life and was of a smaller size, we did not have sufficient 
power to estimate the impact of comparable time periods.  
Different factors may explain why the magnitude of HR depends on the length of follow-up. 
First, over extended follow-up times HR could have a built-in selection bias as a consequence of 
a preferential depletion of susceptible subjects from the high-risk group (here, low 25D status) 
(Hernan 2010). Secondly, a single (baseline) measurement may underestimate the proportion of 
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deficient subjects, as time progresses (differential misclassification), since 25D is expected to 
decrease by age (Gallagher 2013). Potential reasons for such decrease include reduced capacity 
for cutaneous production, or an increase in adipose tissue mass, leading to reduced 25D 
bioavailability (Pereira-Santos 2015).  
We found an inverse relationship between cardiovascular risk and 25D status during the initial 
22 years of follow-up, but not for longer periods. Many studies found similar associations, but 
the strength of these associations varies (Wang 2012, Khaw 2014, Andersson 2010). Others 
have not been able to confirm such relationship (Messenger 2012). Aside from differences in 
the mean age of the cohorts and in 25D categorization, varying follow-up lengths might explain 
the heterogeneity in findings.   
Our results regarding stroke are of a somewhat larger magnitude compared to others (Sun 
2012, Wang 2012, Andersson 2010). Generally, HR for the lowest 25D category varies between 
1.5 and 2 when follow-up is limited to two decades. However the elevated risk of stroke in 
relation to that of a composite CVD is in line with existing knowledge that 25D shows 
associations with some, but not all, cardiovascular endpoints (Andersson 2010). For example, 
25D status was associated with cerebrovascular death, but not coronary death (Kilkkinen 2009), 
suggesting different 25D mechanisms of action on these outcomes.  
Regarding mortality our results are in agreement with many studies (Pilz 2009, Khaw 2014, 
Schöttker 2013). One such study, following 30 000 middle-aged women for 20 years, found a 2-
fold risk among sun avoiders compared to women with the highest sun exposure (Lindqvist 
2014). A recent meta-analysis confirmed a significant inverse relationship for mortality at 25D 
concentrations less than 75 nmol/l, with double the risk in the lowest category ≤22 nmol/l 
(Garland 2014). The authors acknowledge the varying lengths of follow-up as a source of 
substantial heterogeneity and that the observed risk was even higher when time was limited to 
7 years.  
The main strengths of this study include accurate mortality and CVD information from the 
registers and a representative population-based cohort. We previously found that 25D levels in 
these samples were comparable with those expected in fresh blood regarding mean, range and 
winter to summer variation (Leu 2015). Further, categorizing the main exposure, instead of 
including the actual concentrations, should decrease somewhat the amount of misclassification 
bias as many participants are expected to maintain their exposure category throughout the 
follow-up. Another strength is that our 25D distribution-based cutoff is very close to the widely 
accepted level of deficiency (50 nmol/L), which enables the comparison of our results with 
published findings. In contrast, the main weaknesses are the small sample size and the lack of 
repeated 25D measurements. Consequently, we could not determine whether an augmented 
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cardiovascular risk would be present also at very high 25D levels as found by others 
(Michaelsson 2010, Durup 2015). 
In summary, low vitamin D status in mid-life increased the risk of total CVD and particularly of 
stroke within 17 years from the 25D assessment. Lengthier follow-up diminished this risk 
towards the null. Although the association with all-cause mortality was also attenuated, a 
heightened risk was still present after 32 years. The attenuation may be due to changes in 25D 
status that occurred between baseline and end of observation period. Our results, if confirmed 
by studies using repeated assessments of the 25D level, indicate the importance of maintaining 
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Figure 1: Age- and season-adjusted Kaplan-Meier curves for CVD incidence in the lowest 25D quartile 
(continuous line) and the upper three quartiles combined (dashed line). 
 
Figure 2: Age- and season-adjusted Kaplan-Meier curves for stroke incidence in the lowest 25D quartile 






Figure 3: Age- and season-adjusted Kaplan-Meier curves for all-cause mortality in the lowest 25D 








Table 1: Cross-sectional associations between vitamin D (25D) categories and baseline factors (assessed in 1968-
1969) in middle-aged women, the Population Study of Women in Gothenburg, Sweden. Data are presented as 
prevalence percentage across 25D categories for categorical factors and mean (SE) value for continuous factors. 
Factor Categories of 25D p value  
 Low 25D (<=51.45 nmol/L) High 25D (>51.45 nmol/L)  
Age (N=1227): % 0.5a  
                                    38 (n=305) 26.9 73.1  
                                    46 (n=342) 25.7 74.3  
                                    50 (n=368) 25.0 75.0  
                                    54 (n=133) 18.8 81.2  
                                      60 (n=79) 25.3 74.7  
Season of examination (N=1227): % <0.001a 
           Winter (Nov-April), n=861 26.7 73.3  
     Early summer (May-June), n=144 34.7 65.3  
   Late summer (Aug-Oct), n=222 12.2 87.8  
Smoking status (N=1226): % 0.042a 
                               Never (n=647) 22.7 77.3  
                         Ex-smoker (n=90) 21.1 78.9  
             Current smoker  (n=489) 28.8 71.2  
Leisure time physical activity (N=1226): % <0.001a 
         Less than 4h/week (n=219) 34.7 65.3  
          At least 4h/week (n=1007) 22.9 77.1  
Occupational class (OC) (N=1184): % <0.01a 
            Higher employee (n=146) 14.4 85.6  
                        Employee (n=543) 23.8 76.2  
                            Worker (n=495) 28.7 71.3  
Education (N=1222): % 0.02a 
          Elementary school (n=847) 26.8 73.2  
 Secondary school or higher (n=375) 20.3 79.7  
BMI (N=1227) 25.2 (0.27) 23.8 (0.11) <0.001b 
BMI (N=1227): %   <0.001a 
                            Normal (n=817) 21.2 78.8  
                     Overweight (n=313) 26.2 73.8  
                                Obese (n=97) 53.6 46.4  
Diastolic BP, mm Hg (N=1226) 85.3 (0.66) 84.3 (0.35) 0.2b 
Systolic BP, mm Hg (N=1227) 135.5 (1.40) 133.3 (0.70) 0.45c 
Hypertension (N=1225)   0.23 a 
                                   Yes (n=494) 26.5 73.5  
                                    No (n=731) 23.5 76.5  
Waist circumference (N=1226) 76.3 (0.61) 72.8 (0.25) <0.001c 
Total cholesterol, mmol/l (N=1227) 6.9 (0.09) 6.8 (0.04) 0.95c 
Triglycerides, mmol/l (N=1226) 1.3 (0.04) 1.2 (0.02) 0.02c   
a According to the χ2-test of association   b According to the t-test of means 
 cAccording to the Mann-Whitney test of medians  
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Table 2: HR (95% CI) of total CVD, stroke and all-cause mortality for subjects with low vitamin D (25D) status at baseline (≤51.45 nmol/L) 
estimated from Cox proportional hazard analyses. Results are shown for increasing lengths of follow-up time. 
Length of follow-up 17 years (ends 1986) 22 years (ends 1991) 27 years (ends 1996) 32 years (ends 2001) 37 years (ends 2006) 
TOTAL CVD 
Number (%) of events in 
low: high 25D category 
49 (16%): 115 (13%) 73 (24%): 204 (22%) 102 (34%): 336 (36%) 144 (48%): 455 (49%)  
Basic model 1 1.68 (1.18; 2.40)** 1.42 (1.07; 1.88)* 1.16 (0.92; 1.47) (NS) 1.18 (0.97; 1.44) (NS)  
Test of equality of HR current period vs 
previous period 2 
p=0.01 p=0.02 p=0.62  
Adjusted model 3 1.28 (0.88; 1.88) (NS) 1.06 (0.78; 1.42) (NS) 0.82 (0.64; 1.05) (NS) 0.89 (0.72; 1.09) (NS)  
STROKE 
Number (%) of events in 
low: high 25D category 
12 (4%): 14 (2%) 19 (6%): 41 (5%) 27 (9%): 78 (9%) 37 (12%): 128 (14%)  
Basic model 1 3.54 (1.55; 8.09)** 5 1.74 (0.99; 3.08) (NS) 1.32 (0.84; 2.11) (NS) 1.12 (0.77; 1.64) (NS)  
Test of equality of HR current period vs 
previous period 2 
p<0.01 p=0.02 p=0.30  
Adjusted model 4 3.30 (1.37; 7.98)** 5 1.40 (0.76; 2.58) (NS) 0.99 (0.61; 1.61) (NS) 0.84 (0.56; 1.27) (NS)  
ALL-CAUSE MORTALITY 
Number (%) of events in 
low: high 25D category 
47 (15%): 68 (7%) 69 (23%): 134 (15%) 102 (33%): 211 (23%) 
 
144 (47%): 313 (34%) 187 (61%): 449 (49%) 
Basic model 1 2.26 (1.49; 3.43)*** 1.70 (1.24; 2.34)*** 1.65 (1.28; 2.12)*** 1.70 (1.38; 2.09)*** 1.66 (1.38; 1.98)*** 
Test of equality of HR current period vs 
previous period 2 
p=0.10 p=0.12 p=0.77 p=0.17 
Adjusted model 6 2.02 (1.29; 3.16)** 1.47 (1.05; 2.07)* 1.41 (1.07; 1.85)* 1.45 (1.15; 1.81)** 1.43 (1.18; 1.73)*** 
      
1 Model accounts for age at baseline (as a stratification variable) and season of 25D measurement. 
2 Comparison of HR for the current period versus HR corresponding to follow-up stopped 5 years earlier. The p-value corresponds to an 
interaction term between 25D and a binary follow-up indicator (1 if the follow-up time was longer than the end of the previous follow-up period 
and 0 otherwise). See Appendix for details.   
3 Model accounts for season of 25D measurement and baseline waist circumference, leisure time physical activity, hypertension, triglyceride 
level, education, age, smoking and occupational class. Last three factors were included as stratification variables into the model.  
4 Model accounts for season of 25D measurement and baseline waist circumference, leisure time physical activity, education, age, smoking and 




5 Could not be adjusted for season of 25D measurement due to sparse data. 
6 Same adjustment factors as 3 except for education  




This appendix uses the comparison between the hazard ratio for the first 17 years of follow-up 
and the hazard ratio for the first 22 years of follow-up as an example. The same principle applies 
to all comparisons presented in Tables 2-4.   
Denote HR17 the hazard ratio (of a given endpoint) for subjects with low 25D at baseline for the 
first 17 years of follow-up, HR22 the hazard ratio for the first 22 years of follow-up and HR17-22 
the hazard ratio for the period 17-22 years (see Appendix figure). It is of interest to test the null 
hypothesis 𝐻0: 𝐻𝑅17 =  𝐻𝑅22. We show below that this hypothesis is equivalent to testing that 
there is no interaction between the effect of 25D and time i.e. that HR17 and HR17-22 are equal. 
To obtain a p-value corresponding to the null hypothesis for the interaction 𝐻0,𝑖𝑛𝑡: 𝐻𝑅17 =
 𝐻𝑅17−22 we introduce in the Cox regression model an interaction term between 25D and a 
dichotomous follow-up time indicator (follow-up ≤ 17 years vs follow-up >17 years).  
Moreover, HR22 can be expressed as a weighted average between the hazard ratio for the first 




     where w1 and w2 represent weights. 
The null hypothesis of interest 𝐻0(𝐻𝑅17 =  𝐻𝑅22) above becomes 




<=> 𝐻0: 𝑤1𝐻𝑅17 + 𝑤2𝐻𝑅17 = 𝑤1𝐻𝑅17 + 𝑤2𝐻𝑅17−22 
<=> 𝐻0: 𝐻𝑅17 = 𝐻𝑅17−22, which is the same as the null hypothesis for the interaction 
𝐻0,𝑖𝑛𝑡. 
The p-values for the equality of HR estimates across increasing follow-up time (Tables 2 – 5) are 
thus obtained from Cox regression models fitted with interaction terms between 25D and 
follow-up time.   
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